Camp4 Therapeutics Corp
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On September 11, 2026, Richard Young, PhD, amember of our board of directors, adopted a trading plan intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. Pursuant to this plan, Dr. Young may sell up to 50,000 shares of our common stock beginning on December 16, 2026, subject to the terms of the plan. The plan will terminate on or prior to December 15, 2027.
On September 25, 2026, Daniel Tardiff, PhD, our Chief Scientific Officer, adopted a trading plan intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. Pursuant to this plan, Dr. Tardiff may sell up to 51,020 shares of our common stock beginning on December 28, 2026, subject to the terms of the plan. The plan will terminate on or prior to September 24, 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.